Table 2.
Summary of all-causality TEAEs.
| SC 200 mg ponsegromab Q3W | |
|---|---|
| Event | (N = 10) |
| Related to ponsegromab treatment | |
| TEAEs, n | 0 |
| Participants with a treatment-related TEAE, n (%) | 0 (0) |
| Unrelated to ponsegromab treatment | |
| TEAEs, n | 92 |
| Participants with a TEAE, n (%) | 10 (100.0) |
| Participants with maximum grade 1 or 2 TEAE, n (%) | 4 (40.0) |
| Participants with maximum grade 3 or 4 TEAE, n (%) | 5 (50.0) |
| Participants with maximum grade 5 TEAE, n (%) | 1 (10.0) |
| Participants with a serious TEAE, n (%) | 4 (40.0) |
| Participants discontinued from study due to TEAE, n (%) | 1 (10.0) |
| Participants discontinued from study treatment due to TEAE but remained in study, n (%) | 2 (20.0) |
| Participants temporarily discontinued from study treatment, n (%) | 1 (10.0) |
| Common TEAEs, n (%) of participantsa | |
| Anemia | 5 (50.0) |
| Diarrhea | 5 (50.0) |
| Fatigue | 4 (40.0) |
| Nausea | 4 (40.0) |
| Dehydration | 2 (20.0) |
| Dizziness | 2 (20.0) |
| Fall | 2 (20.0) |
| Hypertension | 2 (20.0) |
| Hypokalemia | 2 (20.0) |
| Insomnia | 2 (20.0) |
| Lacrimation increased | 2 (20.0) |
| Neutrophil count decreased | 2 (20.0) |
| Platelet count decreased | 2 (20.0) |
| Upper abdominal pain | 2 (20.0) |
| Vomiting | 2 (20.0) |
aOccurring in >1 participant.